Sort   by:  
 Page size 
GenomicsResponse to the combination of farnesyltransferase inhibitors and gamma-secretase inhibitors in glioblastoma stem cells
Response to the combination of farnesyltransferase inhibitors and gamma-secretase inhibitors in glioblastoma stem cells
PRJNA413807 | ENA
TranscriptomicsExpression data from normal human fibroblasts expressing prelamin A or progerin, untreated or treated with farnesyltransferase inhibitor (FTI)
We compared the transcriptomes of isogenic diploid fibroblasts expressing progerin or elevated levels of wild-type prelamin A with that of wild-type fibroblasts. We subsequently used the reversion towards normal of two phenotypes, reduced cell growth and dismorphic nuclei, by treatment with farnesyl...
ORGANISM(S): Homo sapiens 
2012-08-31 | E-GEOD-40404 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human fibroblasts from patients with HGPS compared to age matched controls treated both control and HGPS fibroblasts with a protein farnesyltransferase inhibitor (FTI)
We analyzed and compared global gene expression changes in fibroblasts from human subjects with HGPS compared to age matched controls. We then treated both control and HGPS fibroblasts with a protein farnesyltransferase inhibitor (FTI), a medication currently used in clinical trials to treat HGPS, ...
ORGANISM(S): Homo sapiens 
2010-06-01 | E-MEXP-2597 | biostudies-arrayexpress
TranscriptomicsResponse to the combination of farnesyltransferase inhibitors and gamma-secretase inhibitors in glioblastoma stem cells
Notch-targeted gamma-secretase inhibitors (GSIs) exhibited limited efficacy in glioblastoma patients. We identified that farnesyltransferase inhibitors (FTIs) increased sensitivity to GSIs in glioblastoma stem cells. To interrogate the mechanisms mediating the interaction between these two classes o...
ORGANISM(S): Homo sapiens 
2017-10-11 | GSE104783 | GEO
ProteomicsRepurposing Farnesyltransferase Inhibitors Tipifarnib and Lonafarnib as Antibacterial Agents: Proteomic and Functional Analyses
Farnesyltransferase inhibitors (FTIs) such as tipifarnib and lonafarnib were originally developed as anticancer agents but have recently been reported to exhibit antibacterial activity against Gram-positive pathogens. The underlying antibacterial mechanism of action, however, remains unknown. Here, ...
ORGANISM(S): Bacillus subtilis subsp. subtilis str. 168 Bacteria 
2026-09-14 | PXD081045 | Pride
Drug repurposing Mode of action Farnesyltransferase inhibitors Proteomics Antibiotics 
UnknownStructure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.
Not available
S-EPMC3045627 | biostudies-literature
UnknownPhenothiazine- and Carbazole-Cyanochalcones as Dual Inhibitors of Tubulin Polymerization and Human Farnesyltransferase.
Not available
S-EPMC10305003 | biostudies-literature
UnknownEffect of farnesyltransferase inhibitors on SARS-CoV-2.
Not available
S-EPMC9711904 | biostudies-literature
UnknownStructurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites.
Not available
S-EPMC2728208 | biostudies-literature
UnknownPreventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors.
Not available
S-EPMC4436830 | biostudies-literature
Sort   by:  
 Page size